Afelimomab for sepsis - horizon scanning review

Record ID 32002000530
Authors' objectives:

To summarise the available evidence on afelimomab for sepsis.

Authors' recommendations: - Clinical impact: The clinical impact associated with the introduction of afelimomab initially appears small and needs further assessment when trial results are fully published. However afelimomab is a new treatment for a patient group that has a very high mortality (50-80%) and any benefit may be clinically significant. - Service impact: It is likely that there will be some service impact associated with the introduction of afelimomab as intensive care staff will need to consider treatment and target treatment to those with high IL-6 levels. - Additional factors: There are unlikely to be any significant additional factors associated with the introduction of afelimomab, although patients and their carers will probably welcome this therapeutic option. - Financial and overall NHS impact: Due to the lack of cost data and detailed estimates of patient group, it is difficult to determine the financial impact of introducing afelimomab for severe sepsis and septic shock at this time. However the numbers of patients currently using costly health services, and eligible for consideration of therapy is significant.
Authors' methods: Overview
Project Status: Completed
Year Published: 2002
URL for published report:
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: England, United Kingdom
MeSH Terms
  • Antibodies, Monoclonal
  • Sepsis
  • Shock, Septic
Organisation Name: NIHR Horizon Scanning Centre
Contact Address: The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
Contact Email:
Copyright: National Horizon Scanning Centre (NHSC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.